Elite Pharmaceuticals, Inc
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 335 M | On Market | 14 | Elite |
Adderall XR | 1.56 B | On Market | 9 | Elite |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Tagi |
Phentermine Capsules | 7.5 M | On Market | 6 | Tagi |
Phentermine Tablets | 40 M | On Market | 8 | Tagi |
Oxycodone IR | 400 M | On Market | 10 | Epic |
Vigabatrin | 275 M | Approved - Launching 2nd half of 2023 | 15 | Pyros |
Doxycycline | 85 M | Approved - Evaluating Market Opportunites | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved - On Hold (Opioid Product) | 4 | ---------- |
Undisclosed Dopamine Agonist | 12 M | Filed with FDA 22 Dec 2022 | ---------- | ---------- |
Undisclosed Antimetabolite | 42 M | Filed with FDA 20 Apr 2023 | ---------- | ---------- |
Generic OxyContin | 517 M | Human Insufflation PK Study | ---------- | ---------- |
Generic Concerta | 1.159 B | In Development | ---------- | ---------- |
Generic Vyvanse | 2.53 B | In Development | ---------- | ---------- |
SequestOx | 400 M | On Hold | ---------- | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | (9,279,321) | ||
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 29 June 2023 | 29 June 2023 |